JPH203 Dihydrochloride is primarily utilized in cancer research due to its role as a selective inhibitor of the L-type amino acid transporter 1 (LAT1). LAT1 is overexpressed in various types of cancer cells, making it a potential target for therapeutic intervention. By inhibiting LAT1, JPH203 Dihydrochloride disrupts the uptake of essential amino acids, such as leucine, into cancer cells, thereby inhibiting their growth and proliferation. This mechanism is particularly promising in the treatment of cancers that are highly dependent on amino acid metabolism, such as certain types of breast, lung, and prostate cancers. Additionally, its selectivity for LAT1 minimizes the impact on normal cells, reducing potential side effects. Research is ongoing to explore its efficacy in preclinical and clinical settings, with the aim of developing it as a targeted cancer therapy.